Oricef

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oricef

What is Oricef? Overview

Property Description
Active ingredient Ceftriaxone (Ceftriaxone sodium)
Form Sterile powder for injection
Pharmacological class Third-generation cephalosporin, β-lactam antibiotic
General Purpose Treatment of serious systemic bacterial infections
Origin Synthetic (semi-synthetic derivative)

What Type of Antibiotic is Oricef?

Oricef is a prescription-only medicine defined as an anti-infective agent. Its core active component is Ceftriaxone (Ceftriaxone sodium), which is classified pharmacologically as a third-generation cephalosporin, a specific group within the β-lactam antibiotics class. This classification signifies its broad-spectrum antibiotic activity and increased stability against common bacterial defense mechanisms.

This synthetic compound is globally recognized for its importance, being included on recognized lists of essential medicines. This affirms that the compound is considered one of the most effective and safe medicines needed in a health system. Oricef is exclusively a single-active-ingredient product used for monotherapy in cases requiring definitive bacterial elimination.


Composition and Pharmaceutical Form

Oricef is provided strictly as a sterile, non-oral powder for injection, a pharmaceutical form required because Ceftriaxone sodium is not effectively absorbed when taken by mouth. This preparation is for parenteral administration—that is, delivery directly into the body via either controlled intravenous injection or deep intramuscular injection.

The necessity of the sterile powder for injection ensures that the full dose, upon reconstitution with a suitable diluent, rapidly and completely enters the systemic circulation. This process allows the medicine to quickly achieve the high therapeutic concentrations necessary to manage severe systemic bacterial infections effectively.


General Purpose and Core Action

Its general purpose is to treat serious systemic bacterial infections by employing a definitive bactericidal action against the causative pathogens. This compound actively kills susceptible organisms rather than merely inhibiting their growth. This potent effect stems from its ability to disrupt the structural integrity of the bacterial cell wall, serving as a crucial, broad-spectrum antibiotic for achieving the resolution of established infections.

What side effects are possible with Oricef?

Possible Side Effects and Safety Information

The safety profile for Oricef (Ceftriaxone) is derived from official regulatory documentation, which classifies possible side effects primarily by frequency and the body system affected.

Frequency-Classified Adverse Reactions

Classification Examples of Officially Documented Reactions
Common Changes in blood counts, such as eosinophilia or thrombocytosis; elevated liver enzymes (SGOT/SGPT); diarrhea; and local reactions like pain at the injection site.
Uncommon Granulocytopenia, anemia, rash, or fever.
Rare Severe gastrointestinal inflammation, such as Pseudomembranous colitis (Clostridioides difficile-associated diarrhea), or hypersensitivity reactions like bronchospasm or urticaria.

Serious Safety Considerations

The official label highlights several serious, clinically significant adverse reactions. These include the potential for anaphylactic shock and severe, sometimes fatal, hypersensitivity reactions. Severe complications such as haemolytic anemia and severe cutaneous adverse reactions (SCARs) are also documented.

Population-Specific Safety Constraints

Oricef is contraindicated in certain patient groups, with the most critical restriction applying to neonates. It must not be administered simultaneously with any calcium-containing intravenous solutions, due to the documented risk of precipitation of ceftriaxone-calcium salts in the lungs and kidneys. Furthermore, it is contraindicated in hyperbilirubinaemic neonates due to the risk of kernicterus. Patients with severe concurrent renal and hepatic dysfunction require careful consideration, as the half-life of the medicine may be prolonged.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose with Oricef (Ceftriaxone) must be managed as a medical emergency; official guidance mandates that users seek immediate medical attention and contact emergency services without delay.

Documented Manifestations and Severe Outcomes

Regulatory documents state that an excessive exposure may initially manifest with gastrointestinal disturbances, including nausea, vomiting, and diarrhea. At significantly high systemic concentrations, the overdose may progress to involve neurological disturbances such as convulsions or seizures and signs of central nervous system (CNS) excitation.

The most severe, life-threatening outcome officially documented is the risk of Ceftriaxone-calcium precipitation, which can occur in major organs like the lungs and kidneys. This specific toxicity risk necessitates close clinical monitoring and potential hospital observation. Patients with pre-existing renal impairment or hepatic impairment are noted to be at a higher risk for this accumulation and associated complications.

Regulatory Treatment Status

Official labeling notes that management is strictly symptomatic and supportive. There is no specific antidote known for Ceftriaxone. Furthermore, regulatory documents specify that the compound is not effectively removed from the body by standard procedures, such as hemodialysis or peritoneal dialysis.

Therapeutic Uses of Oricef

What Oricef Treats: Main Uses and Benefits

Oricef (Ceftriaxone) is an injectable antibiotic generally reserved for treating conditions marked by increased physiological stress caused by severe bacterial infections. Its primary benefit may assist with managing the severity of acute bacterial presence in critical scenarios. This medicine is commonly used across conditions presenting with acute, disruptive episodes, focusing on supportive symptom management.


Therapeutic Scope and Benefits

This medication is commonly applied in clinical settings that involve acute or unstable symptom patterns, such as conditions associated with acute or disruptive episodes like Sepsis (bloodstream infection), complicated Pneumonia, severe bone and joint infections, and Bacterial Meningitis. It is also relevant in contexts involving deep-seated or anatomically protected infections where symptoms create noticeable physiological strain, including high, persistent fever, uncontrollable shaking chills, and acute systemic imbalance. Oricef is used for managing infections like Gonorrhea and as a short-term supportive measure (surgical prophylaxis) in high-risk procedures. This contributes to easing the overall symptom load and supports patients during difficult episodes.

“This medication is typically applied in clinical scenarios demanding rapid, supportive assistance against severe bacterial activity across multiple body systems.”


Quick Fact: Symptomatic Support
Oricef helps address symptom clusters like high fever and chills that interfere with daily functioning during periods of acute infection, supporting general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Oricef (ceftriaxone) is a prescription antibiotic generally used to treat a variety of bacterial infections. However, its use is not appropriate for all patients and requires careful consideration of individual health history.

Who Can Use Oricef?

Oricef is typically used in patients who have a confirmed or strongly suspected bacterial infection susceptible to ceftriaxone. It is frequently prescribed for both adults and children, although dosage adjustments may be necessary based on weight and age.

  • Patients with Infections: Individuals suffering from susceptible infections such as certain types of meningitis, lower respiratory tract infections, skin infections, and urinary tract infections.

Who Cannot Use Oricef?

Oricef is contraindicated (should not be used) in patients with specific conditions to prevent potentially severe reactions and complications:

  • Allergy to Cephalosporins: Patients with a known history of hypersensitivity or severe allergic reaction to ceftriaxone, other cephalosporin antibiotics (like cefdinir or cefalexin), or other beta-lactam antibiotics (like penicillin).
  • Neonates with Hyperbilirubinemia: Newborns (especially premature infants and those up to 28 days old) with high levels of bilirubin in the blood should not receive Oricef due to the risk of bilirubin displacement and potential serious neurological harm.
  • Concomitant Calcium IV Administration (Neonates): Oricef must not be administered simultaneously with intravenous calcium-containing solutions to any patient, but this is an absolute contraindication in neonates due to the risk of fatal precipitation in the lungs and kidneys.

Use with Caution

Certain pre-existing medical conditions require a cautious approach and careful monitoring when using Oricef:

  • Kidney or Liver Impairment: Patients with significant kidney or liver disease may require dosage adjustment.
  • Gastrointestinal Disease: Individuals with a history of colitis or other severe stomach/bowel diseases should be monitored closely, as Oricef may worsen these conditions.

What should I know about interactions with other medicines?

The official interaction profile for Oricef (Ceftriaxone) is defined by a strict set of regulatory constraints, primarily concerning chemical and physical incompatibilities with intravenous products.

Interacting Substance/Class Official Interaction Classification
Calcium-containing IV Solutions Contraindicated (in neonates le 28 days)
Lidocaine Solutions (IV route) Contraindicated (approved only for IM injection)
Hyperbilirubinemic Neonates Contraindication (risk of bilirubin displacement)

Mandatory Administration Constraints

Ceftriaxone must not be mixed or administered simultaneously with any calcium-containing intravenous solution in the same infusion line for patients of any age due to the risk of precipitate formation. This prohibition extends to diluents containing calcium, such as Ringer's or Hartmann's solutions. In patients older than 28 days, these substances may be administered sequentially if the IV lines are thoroughly flushed between infusions. Furthermore, the medicine is physically incompatible with several other substances, including Vancomycin, Amsacrine, and Fluconazole, and must not be mixed with them.

Documented Pharmacodynamic and Exposure Interactions

Co-administration with Aminoglycoside Antibacterials may lead to an increased risk of nephrotoxicity and ototoxicity. Use with Coumarin Anticoagulants (e.g., Warfarin) may increase the effect of the anticoagulant, leading to a heightened risk of bleeding. The efficacy of Estrogen-Containing Oral Contraceptives may be decreased when used with Ceftriaxone. An antagonistic effect has been observed in vitro with bacteriostatic antibiotics such as Chloramphenicol.

Mechanism of Action

Oricef's core function is executed through a definitive bactericidal mechanism that structurally compromises susceptible bacterial cells, which leads to the complete elimination of these cells rather than merely inhibiting growth.


Irreversible Inhibition of Cell Wall Assembly

Oricef achieves its effect by acting as an irreversible inhibitor of essential bacterial Penicillin-Binding Proteins (PBPs), the enzymes responsible for cross-linking the structural polymer peptidoglycan. This molecular action immediately halts the final construction of the rigid bacterial cell wall.


Catastrophic Osmotic Lysis

The inhibition of PBPs leads to a critically weakened and unstable cell wall structure, which can no longer withstand the high internal fluid pressure (osmotic pressure) of the bacterial cell. This pressure imbalance results in rapid, catastrophic rupture (lysis), achieving the direct, lethal bactericidal effect on the pathogen population.


️ Structural Mechanisms of Evasion

The mechanism is functionally limited by microbial defense mechanisms, such as the production of certain beta-lactamase enzymes that chemically inactivate the drug before it reaches its target, or through the evolution of altered PBPs with reduced binding affinity.

Dosage and Administration Information

How to Use Oricef (Cefradine) — Administration Guidelines

This section outlines the administration and dosing instructions for Oricef (Cefradine). It does not contain information on therapeutic uses, mechanism of action, or safety.

Administration Requirements

Field Instruction
Route of Administration Oral (swallowed by mouth)
Dosage Form Powder for Oral Suspension (requires preparation)
Dispensing Restriction Prescription-only medicine; dispensing without a valid prescription is prohibited.

Dosing and Schedule

Dosage is determined by a healthcare professional and is highly dependent on the patient's age and weight, particularly for pediatric patients.

Population Dosing Rule
Pediatric Dosing Daily doses for children are calculated based on weight, generally ranging from 25 to 50 mg per kilogram of body weight per day (mg/kg/day). Doses for conditions like otitis media may range higher, up to 75 to 100 mg/kg/day.
Frequency The total calculated daily dose must be divided into equal portions. Administration must occur at fixed intervals, typically every 6 hours or every 8 hours.

Procedural Summary

Correct use requires the following steps:

  1. Obtain the reconstituted Oricef (Cefradine) Oral Suspension from a licensed dispenser with a valid prescription.
  2. Calculate the precise daily dose based on the patient's weight, as directed.
  3. Divide the total daily dose into the required number of equal portions.
  4. Administer the medicine orally according to the set schedule (e.g., every 6 or 8 hours) to maintain consistent intervals.

These instructions define the standardized protocol for how the medicine must be prepared and taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Oricef

Evidence for Use in Skin and Skin Structure Infections

Research for this indication was evaluated in studies exploring how symptoms change over time. These studies involved several short-term randomized controlled trials (RCTs) and various other prospective and retrospective studies. These research efforts monitored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level, assessing the evolution of infection symptoms.

Studies reported measurements of clinical cure or favorable response achieved by patients at the follow-up visit. However, the follow-up durations were limited in many of the studies, which means that long-term effects are not fully established, particularly concerning the recurrence of the infection. The results apply only to the populations studied.


Evidence for Use in Urinary Tract Infections (UTIs)

Oricef was studied for use in conditions characterized by acute or disruptive episodes like uncomplicated UTIs. The evidence includes both active-controlled, randomized trials and studies monitoring drug concentration levels in the urine. Research explored outcomes linked to inflammatory or irritative states and patient-reported outcomes describing perceived discomfort.

Trials reported measurements related to the proportions of patients showing a sterile urine culture after the study interval. Certainty remains low in some areas because a number of the available comparative trials are historical and may not fully reflect current bacterial susceptibility patterns. Limited information is available for long-term outcomes or recurrence rates following treatment.


Evidence for Use in Pharyngitis and Tonsillitis

Research exploring Oricef in throat infections, conditions involving periods of heightened symptoms, includes meta-analyses that synthesize data from multiple randomized controlled trials and open-label comparative studies. This research examined microbiological outcomes (clearance of S. pyogenes) and outcomes describing episodic or acute changes.

Comparative trials described patterns observed in the studies related to symptom changes and included various control groups. The follow-up durations were limited primarily to the post-treatment assessment period, and data for long-term outcomes, such as the prevention of rare, delayed complications, are not fully established.


Evidence in Special Populations and Research Gaps

Oricef was evaluated in studies including pediatric populations and older adult patients. These studies help show what has been observed so far in terms of measured changes. However, data for certain groups remain insufficient, particularly for pregnant individuals or patients with certain significant pre-existing health conditions.

Evidence quality varies across studies, and the comparative evidence is lacking against many of the newest antibiotic therapies. This research provides context but does not determine whether an individual will respond similarly to the group patterns observed in the trials.

Frequently Asked Questions (FAQ)

Common questions about Oricef (FAQ)

Q: Can Oricef be used to treat viral infections?

Oricef is classified as an antibacterial drug. Official product information states that it is specifically used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. It does not have approved uses or indications for treating conditions or illnesses that are caused by viruses.


Q: Does Oricef have a generic version available?

The active ingredient in Oricef, Ceftriaxone sodium, is the chemical basis for generic preparations of the drug, which may be available in different health systems. While the name Oricef is a brand name, the core chemical component is generally available under its generic name.


Q: What is the expected duration of treatment with Oricef?

The total duration of treatment is determined by the specific type of infection being treated. Official guidelines generally recommend administration be continued for at least 48 to 72 hours after a fever has resolved or bacterial eradication has been achieved. The overall length of the course is a determination made by a healthcare professional.


Q: Can you stop taking Oricef once symptoms improve?

Official patient instructions indicate that the full course is typically administered, even if symptoms appear to improve quickly. Early discontinuation or missed doses are understood to pose a risk of incomplete bacterial eradication and may relate to the development of antibiotic resistance.


Q: Is Oricef the same as Cefadroxil?

No, Oricef (Ceftriaxone) is classified as a third-generation cephalosporin antibiotic. Cefadroxil is a distinct active ingredient that belongs to the first-generation cephalosporin class. While both are beta-lactam antibiotics, they are different compounds used to treat different ranges of susceptible bacteria.


Q: Is it normal to feel tired while taking Oricef?

Official patient information materials sometimes list tiredness or general fatigue as a possible symptom. Official information indicates that any concerning symptoms, such as unusual or severe weakness, should be reviewed by a healthcare provider.


Q: Can Oricef affect your sleep?

Regulatory documents have reported potential side effects affecting the nervous system, including somnolence (drowsiness or lethargy) and, in rare cases, other disturbances of consciousness. These effects are generally observed to resolve after the medication is discontinued.


Q: Does Oricef interact with common pain relievers like ibuprofen?

Regulatory drug interaction checkers typically indicate that there is no known interaction between Ceftriaxone and common pain relievers such as Ibuprofen. General patient safety practice involves reviewing all medicines, including over-the-counter products, with a healthcare professional.


Q: Is it necessary to avoid alcohol completely while taking Oricef?

Official product information notes that, unlike some antibiotics, Ceftriaxone is not associated with causing a severe reaction (like a disulfiram-like effect) when mixed with alcohol. General patient guidelines often suggest the use of alcohol be discussed with a healthcare professional while undergoing treatment.


Q: Can breastfeeding parents use Oricef?

Official regulatory information confirms that Ceftriaxone is excreted in small amounts in breast milk. Although the risk to the infant is considered small, it may potentially cause minor changes to the infant’s intestinal flora. Decisions about using this medicine while breastfeeding are typically made in consultation with a healthcare professional.


Q: Have there been recent clinical trials related to Oricef?

Yes, official databases like the NIH ClinicalTrials.gov registry show that active clinical research studies involving the use of the active ingredient Ceftriaxone continue to take place. This research often focuses on optimizing advanced dosing strategies and exploring its use in severe conditions.


Q: What happens if a dose of Oricef is missed?

Patient guidelines state that a missed dose may be taken as soon as the patient recalls it. If it is close to the next scheduled dose, official directions indicate that the missed dose is usually skipped, and the regular schedule is continued. It is generally advised not to take two doses to compensate for a single missed dose.


Q: Does Oricef make you sensitive to sun exposure?

Ceftriaxone, which belongs to the cephalosporin class, is not generally listed as a medication that causes increased sun sensitivity (photosensitivity) in official regulatory safety documents. Other antibiotic classes are more commonly associated with this specific effect.


Q: How is Oricef eliminated from the body?

Official pharmacokinetic information indicates the medicine is removed from the body through two primary routes. A portion of the drug is excreted as unchanged medicine through the urine, and the remainder is secreted in the bile, where it is then found in the feces as inactive compounds.


Q: Does Oricef change the way laboratory blood tests work?

Official safety information reports that Ceftriaxone may potentially interfere with certain diagnostic tests. This interference includes causing a false-positive result for the Coombs' test, and it may also affect some non-enzymatic methods used for checking glucose levels in the urine.


Q: Do any official sources recommend waiting before driving or operating machinery after taking Oricef?

Official documents note that side effects such as dizziness or somnolence (drowsiness) have been reported. If such effects are experienced, official documents indicate that the ability to drive or operate machinery may be affected.


Q: How quickly does Oricef typically start working after the first dose?

Official patient information often states that a patient should expect to begin feeling an improvement in symptoms within the first few days of starting treatment. If symptoms do not improve or if they worsen, this change in status may warrant a review by a healthcare provider.


Q: Are there any long-term side effects associated with Oricef use?

Official regulatory labels focus primarily on acute and common side effects experienced during or shortly after treatment. While some research summaries note that long-term effects are not fully established, the official labels do not define or list a specific category of long-term side effects for this medicine.


Q: What signs might indicate an unexpected or serious side effect from Oricef?

Official patient materials describe signs of a severe allergic reaction that are associated with the need for immediate medical review, such as hives, swelling of the face or tongue, or trouble breathing. Other serious signs include severe gastrointestinal symptoms like bloody diarrhea or intense stomach pain.


Q: What information is available about Oricef use during pregnancy?

Regulatory information indicates that the medicine crosses the blood placenta barrier. Official guidance advises that it should be used in pregnancy only if a healthcare provider determines the potential benefits outweigh any potential risks. The patient's pregnancy status is a necessary consideration for the healthcare provider when determining use.


Q: Is Oricef safe for older adults (geriatric population)?

Official guidance states that, for older adults, the recommended adult dosages usually require no modification as long as their renal and hepatic function (kidney and liver function) is satisfactory. Close clinical monitoring for safety and effectiveness in this population is generally part of routine care.


Q: Can Oricef be taken with dietary supplements like iron or calcium?

Ceftriaxone is strictly contraindicated (must not be mixed) with intravenous calcium solutions due to the risk of precipitate formation. While the interaction with oral calcium supplements is generally not listed as a contraindication, it is standard practice to discuss all supplements, including iron and calcium, with a healthcare professional.


Q: What does 'contraindication' mean regarding Oricef?

The term contraindication means that the medicine should not be used by a patient who has a specific, pre-existing condition or characteristic. For Oricef, examples include a known allergy to the drug or, in newborns, high levels of bilirubin, as using the drug in these cases carries a high risk of complications.

How should Oricef be stored and disposed of?

Storage and Disposal of Oricef (Ceftriaxone for Injection)

Product Form Temperature Requirement Stability Constraint
Dry Powder (Unopened) Controlled Room Temperature (15 C to 30 C) Store in original container and protect from light.
Reconstituted Solution Refrigeration (2 C to 8 C) Must be used or discarded within 48 hours. Do not freeze.

All forms of Oricef must be stored out of the sight and reach of children to ensure safety. The solution should never be prepared using calcium-containing diluents. Unused or expired medication should be disposed of via a drug take-back program when available, or by following specific governmental guidelines for non-flushable pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oricef found in:

A-Z Index: